IRVINE, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its second quarter ended June 30, 2022.
Second Quarter Revenue and Business Highlights
- Generated revenue of $92.7 million in the second quarter of 2022, up 7% sequentially from the first quarter, and 46% over the same quarter last year.
- Accelerated the expansion of our US commercial footprint, finishing the quarter with over 270 territories, just shy of our full year target.
- Announced FDA clearance and limited market release of two new products, one of which targets patients outside of our core TAM.
- Ended the quarter with $330.5 million in cash, cash equivalents and short-term investments.
“We continue to execute crisply across all of our growth drivers despite the ongoing challenges to the med tech operating environment”, said Bill Hoffman, CEO of Inari Medical. “We produced robust revenue growth, hired our largest class of new sales professionals and initiated the limited market release of two new products, including one that targets patients beyond our core TAM. We remain committed to our mission, and to ideas bigger and more important than just business. We are thankful for your support of our work.”
Second Quarter 2022 Financial Results
Revenue was $92.7 million for the second quarter of 2022, compared to $86.8 million for the prior quarter and $63.5 million for the second quarter of 2021. The increase over prior periods was driven by continued U.S. commercial expansion and new product introductions.
Gross profit was $82.4 million for the second quarter of 2022, compared to $58.6 million for the same period of 2021. Gross margin was 88.8% for the second quarter of 2022, compared to 92.4% for the same period in the prior year, lower primarily due to the move to our larger production facility in the fourth quarter of 2021.
Operating expenses for the second quarter of 2022 were $91.7 million, compared to $54.5 million for the second quarter of 2021. The increase was mainly driven by personnel-related expenses as we increased headcount to fund the expansion of the commercial, research and development, clinical, and support organizations.
Net loss was $10.2 million for the second quarter of 2022 and net loss per share was $0.19 on a weighted-average basic and diluted share count of 53.2 million, compared to a net income of $4.1 million and a net income per share of $0.08 and $0.07 on a weighted-average basic share count of 49.7 million and diluted share count of 55.6 million, respectively, in the same period of the prior year.
Full-Year 2022 Revenue Guidance
For the full year 2022, we are reaffirming our revenue guidance range of $360 million to $370 million.
Webcast and Conference Call Information
Inari Medical will host a conference call to discuss the second quarter 2022 financial results after market close on Wednesday, August 3, 2022 at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time. The conference call can be accessed live by registering here.
About Inari Medical, Inc.
Inari Medical, Inc. is a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases. Our current product offering consists of two minimally invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The company purpose-built its products for the specific characteristics of the venous system and the treatment of the two distinct manifestations of venous thromboembolism, or VTE: deep vein thrombosis and pulmonary embolism. The ClotTriever system is 510(k)-cleared by FDA and CE marked for the non-surgical removal of clot from peripheral blood vessels, including for the use in the treatment of deep vein thrombosis. The FlowTriever system is 510(k)-cleared by FDA and CE marked for the non-surgical removal of clot from peripheral blood vessels, including for the use in the treatment of pulmonary embolism and clot in transit in the right atrium.
Forward Looking Statements
Statements in this press release may contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. Forward-looking statements include estimated full year 2022 revenue, and are based on Inari’s current expectations, forecasts, and assumptions, are subject to inherent uncertainties, risks and assumptions that are difficult to predict, and actual outcomes and results could differ materially due to a number of factors. These and other risks and uncertainties include those described more fully in the section titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the period ended December 31, 2021, and in its other reports filed with the U.S. Securities and Exchange Commission. Forward-looking statements contained in this announcement are based on information available to Inari as of the date hereof and are made only as of the date of this release. Inari undertakes no obligation to update such information except as required under applicable law. These forward-looking statements should not be relied upon as representing Inari’s views as of any date subsequent to the date of this press release. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Inari.
INARI MEDICAL, INC.
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)
(in thousands, except share and per share data)
|Three Months Ended June 30,||Six Months Ended June 30,|
|Cost of goods sold||10,347||4,814||20,314||9,437|
|Research and development||18,569||11,630||34,704||19,793|
|Selling, general and administrative||73,156||42,897||136,888||79,795|
|Total operating expenses||91,725||54,527||171,592||99,588|
|(Loss) income from operations||(9,328||)||4,112||(12,410||)||11,825|
|Other income (expense)|
|Other income (expense)||252||7||228||(34||)|
|Total other income (expenses)||393||(32||)||346||(78||)|
|(Loss) income before income taxes||(8,935||)||4,080||(12,064||)||11,747|
|Provision for income taxes||1,252||12||1,252||210|
|Net (loss) income||$||(10,187||)||$||4,068||$||(13,316||)||$||11,537|
|Other comprehensive income (loss)|
|Foreign currency translation adjustments||(291||)||57||(408||)||(123||)|
|Unrealized (loss) gain on available-for-sale debt securities||(125||)||(6||)||(373||)||12|
|Total other comprehensive (loss) income||(416||)||51||(781||)||(111||)|
|Comprehensive (loss) income||$||(10,603||)||$||4,119||$||(14,097||)||$||11,426|
|Net (loss) income per share|
|Weighted average common shares used to compute net |
(loss) income per share
INARI MEDICAL, INC.
Condensed Consolidated Balance Sheets
(in thousands, except share data)
|Cash and cash equivalents||$||79,724||$||92,752|
|Short-term investments in debt securities||250,772||83,348|
|Accounts receivable, net||49,171||42,351|
|Prepaid expenses and other current assets||4,997||5,694|
|Total current assets||411,338||245,198|
|Property and equipment, net||20,076||16,471|
|Operating lease right-of-use assets||46,653||44,909|
|Deposits and other assets||6,195||981|
|Long-term investments in debt securities||—||3,983|
|Liabilities and Stockholders' Equity|
|Accrued expenses and other current liabilities||8,076||10,737|
|Operating lease liabilities, current portion||465||802|
|Total current liabilities||40,984||42,513|
|Operating lease liabilities, noncurrent portion||28,196||28,404|
|Other long-term liability||1,304||1,416|
|Commitments and contingencies|
|Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares|
issued and outstanding as of June 30, 2022 and December 31, 2021
|Common stock, $0.001 par value, 300,000,000 shares |
authorized as of June 30, 2022 and December 31, 2021; 53,305,825
and 50,313,452 shares issued and outstanding as of June 30, 2022 and
December 31, 2021, respectively
|Additional paid in capital||445,807||257,144|
|Accumulated other comprehensive loss||(1,183||)||(402||)|
|Total stockholders' equity||413,778||239,209|
|Total liabilities and stockholders' equity||$||484,262||$||311,542|